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Abstract
Background: Thorough knowledge of the regulatory requirements is a challenging prerequisite
for conducting multinational clinical studies in Europe given their complexity and heterogeneity in
regulation and perception across the EU member states.
Methods: In order to summarise the current situation in relation to the wide spectrum of clinical
research, the European Clinical Research Infrastructures Network (ECRIN) developed a
multinational survey in ten European countries. However a lack of common classification
framework for major categories of clinical research was identified, and therefore reaching an
agreement on a common classification was the initial step in the development of the survey.
Results: The ECRIN transnational working group on regulation, composed of experts in the field
of clinical research from ten European countries, defined seven major categories of clinical research
that seem relevant from both the regulatory and the scientific points of view, and correspond to
congruent definitions in all countries: clinical trials on medicinal products; clinical trials on medical
devices; other therapeutic trials (including surgery trials, transplantation trials, transfusion trials,
trials with cell therapy, etc.); diagnostic studies; clinical research on nutrition; other interventional
clinical research (including trials in complementary and alternative medicine, trials with collection
of blood or tissue samples, physiology studies, etc.); and epidemiology studies. Our classification
was essential to develop a survey focused on protocol submission to ethics committees and
competent authorities, procedures for amendments, requirements for sponsor and insurance, and
adverse event reporting following five main phases: drafting, consensus, data collection, validation,
and finalising.
Conclusion: The list of clinical research categories as used for the survey could serve as a
contribution to the, much needed, task of harmonisation and simplification of the regulatory
requirements for clinical research in Europe.
Background
Clinical research plays a vital part in making progress
towards better knowledge, understanding of human
health and disease and the development of new, safe and
effective treatments. In Europe, at the national and at the
European levels, there is a huge amount of pertinent leg-
islation and guidance to clinical research and a thorough
knowledge of the regulatory requirement is a prerequisite
for supporting and conducting multinational clinical
research. At the EU level, five key Directives are related to
clinical research [1-5] and aim to provide a common leg-
islative framework. However, the EU member states
implemented the Directives into national laws with vary-
ing interpretation, thereby prevented the intended harmo-
nisation of regulatory requirements. Therefore, it is not
surprising that the conduct of international academic clin-
ical research is highly complex and may hinder academic
sponsors without support of a large team or a supportive
structure as it is the case for big pharmaceutical companies
or clinical research organisations (CROs) [6]. The aca-
demic research community in Europe needs an infrastruc-
ture to support their international clinical trials.
Supported by grants from the Sixth and Seventh Frame-
work Programmes (FP6 and FP7), the European Clinical
Research Infrastructures Network (ECRIN) was created to
provide support to multinational clinical studies in
Europe for the benefit of patients [7]. ECRIN is based on
the connection of national networks of academic clinical
research centres and clinical trials units from Austria, Den-
mark, Finland, France, Germany, Hungary, Ireland, Italy,
Spain, and Sweden, Switzerland, and the United King-
dom. Each country has both one senior representative
who is member of the governing body of ECRIN repre-
senting his national network and one European corre-
spondent (trained in clinical research) working at the
national coordination on the implementation of the
ECRIN project.
During the FP6- funded project (TWG), different transna-
tional working groups including at least one expert from
each country participating in ECRIN, were established for
analysing the context of clinical research in European
countries and for preparing procedures and guidance doc-
uments to support the set-up and management of multi-
national studies. One of these groups was in charge of
collecting the status of national regulations covering the
whole spectrum of clinical research and the correspond-
ing operating procedures. In order to achieve this objec-
tive, the group planned to design and conduct an
international survey. As no commonly accepted defini-
tions of clinical research categories existed in Europe, the
first step in designing this survey was to delineate the rel-
evant categories of clinical research, as interpreted by theTrials 2009, 10:95 http://www.trialsjournal.com/content/10/1/95
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ten regulation experts of the working group or currently
defined by national laws.
Such a common categorisation could help investigators to
deal with the current lack of harmonisation in a system-
atic way and, hopefully, be also of use to regulators and
legislators in achieving harmonisation. The European
Commission plans to perform by 2010 an assessment of
the application of Directive 2001/20/EC, which specifi-
cally regulates the clinical trials with investigational
medicinal products, with a view to make, if appropriate,
legislative proposals. Therefore, the timing of the ECRIN
survey which has a wider scope not limited to clinical tri-
als with medicinal products only appears appropriate.
This article describes the development of the survey and
the difficulties faced when trying to reach an agreement
on the categories of clinical research, but the detailed
results of the survey will be presented and discussed in fur-
ther publications.
Methods
Definition of categories of research and development of 
the survey
The ECRIN working group on regulatory requirements
and interaction with competent authorities was com-
posed of two chairpersons and at least two representatives
from each ECRIN national network (Austria, Denmark,
France, Germany, Hungary, Ireland, Italy, Spain, Sweden,
and United Kingdom): one expert in the field of regula-
tions and regulatory requirements and the European cor-
respondent.
The objective of the group was to collect information on
current legislation and on the regulatory framework in the
ten European countries previously listed. During the
development of the survey the group experienced difficul-
ties in reaching common understanding on the different
major categories of clinical research. The group therefore
embarked on this task as part of the development of the
survey, in order to achieve common categories, having
unanimous definitions and meanings.
The working tool used to achieve this objective was a
standardised survey and its development underwent five
main phases: drafting, consensus, data collection, valida-
tion and finalising.
Drafting phase
The objective of the survey was to analyse the regulatory
situation and practices and provide the investigators and
sponsors with a comprehensive status of regulatory
requirements covering the whole spectrum of clinical
research helping them to perform multinational studies.
The first step was to find common categories of research
as basis for discussing the regulatory requirements to
which the survey questions can be applied. The first pro-
posal of categories was based on the similarity of key
aspects in definition and meaning in national require-
ments.
Consensus phase
In order to ensure that the final version considered all
national specificities and expressed an agreed common
definition for clinical research categories, the members of
the working group were contacted and invited to provide
feedback on the proposed research categories and ques-
tions in the survey by e-mail and during teleconferences
Data collection phase
The survey was sent by email to the experts. The non-
respondents were contacted again by email, then if neces-
sary by phone in order to obtain all missing data. All the
people contacted responded the survey.
In order to provide comprehensive responses, for each cat-
egory and subcategory of clinical research, detailed ques-
tions were asked regarding regulatory requirements. In
addition, questions with free text answers were included
in order to allow the responders to give further details.
The completed survey was analysed by the leaders of the
working group on regulatory requirements and interac-
tion with competent authorities. When needed, the
experts were interviewed by phone to give further infor-
mation and explanation relating to the answers given on
the survey. The preliminary results were discussed within
the working group during several teleconferences and in
face-to-face ECRIN meetings in Paris (19 and 20 May
2007) and in Brussels (19 and 20 May 2008).
Based on the final discussions the definition of categories
were fine tuned and adapted to include national specifici-
ties.
Validation and finalising phase
The categorisation as well as the results of the survey were
finalised by an informal validation step of representatives




The entire spectrum of clinical research was divided into
seven major categories of clinical research to which the
survey questions were applied [table 1]. The categories of
clinical research defined by the working group are: the
clinical trials on medicinal products (the only categoryTrials 2009, 10:95 http://www.trialsjournal.com/content/10/1/95
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already regulated as such at European level); clinical trials
on medical devices; other therapeutic trials (including the
group of surgery trials, transplantation trials, transfusion
trials, trials with cell therapy, etc.); diagnostic studies;
clinical research on nutrition; other interventional clinical
research (including trials in complementary and alterna-
tive medicine, trials with collection of blood or tissue
samples, physiology studies, etc.); and epidemiology
studies.
The criteria to classify the different types of research are
not uniform in Europe so that the appropriate rules can be
applied in each case. The 2001/20/EC Directive defines
two distinct categories of research: clinical trials (using an
investigational medicinal product) and non-interven-
tional trials (without medicinal product, without addi-
tional diagnostic or monitoring and where a medicinal
product is used according to market authorisation). These
definitions are interpreted differently from country to
country leading some clinical research to be considered as
clinical trial in one country and as non-interventional trial
in another.
An intervention can be considered from a methodological
point of view, that is the introduction of a procedure dic-
tated by a clinical research protocol, e.g., allocation to an
intervention arm by randomisation, while from a health-
care point of view an intervention relates to how invasive
or dangerous it is for the participants (e.g., in relation to
collecting additional blood samples or performing addi-
tional diagnostic tests, or to the insufficiency of previous
safety knowledge on the studied drug or procedure). The
Table 1: Seven major categories of clinical research
Categories Includes
Clinical trials on medicinal products -phase I to IV trials
-biotherapy trials (gene therapy, tissue engineering and cell therapy)
-biopharmaceutical trials 
(blood-derived products, monoclonal antibodies, recombinant proteins)
-vaccines trials
-fixed combination of medicinal products
-multimodal trials
Clinical trials on medical devices -devices alone
-devices combined with medicinal products
Devices are considered either as authorised (bearing the European conformity (CE) label and 
used within its indication or intended purpose), or as non-authorised 
(non CE labelled or used in another indication)




-trials with cell therapy 
(when the cell preparation is not considered as an investigational medicinal product)
-physical therapy trials
-psychotherapy trials (without medicinal product)
Diagnostic studies -diagnostic or imaging studies without medicinal product or medical device
Clinical research on nutrition -nutritional studies
-studies on nutritional supplements
Other interventional clinical research -complementary and alternative medicine,




Epidemiology -interventional and non-interventional pharmacoepidemiology
-interventional and non-interventional epidemiology
-retrospective studies
-registries of patientsTrials 2009, 10:95 http://www.trialsjournal.com/content/10/1/95
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clinical definition of an intervention is independent of the
study design. Unfortunately, the 'legal' definition of 'non-
interventional', as described in the EU Directive 2001/20/
EC for clinical trials with medicinal products appears to
mix up both criteria, which make the interpretation diffi-
cult. In future regulatory definitions it would be desirable
to incorporate all these aspects into a more meaningful
concept. We also propose to separate therapeutic interven-
tion compared to diagnostic intervention.
In addition to our concept of seven categories, we advo-
cate protecting the enrolled participants using categories
of perceived risk (understood as probability and severity
of potential harm). Some member states (e.g., France) are
already considering the risk-based approach. A related
issue refers to what is meant by epidemiological studies or
methods since it can be understood as synonymous to
observational studies, i.e., non-interventional in the
methodological sense. It would be better if future legal
categories will define clinical study categories terms oper-
ationally rather than semantically.
Survey
As the objective of the survey is to provide a comprehen-
sive status of regulatory requirements the questions
focused on the protocol submission to ethics committees
and competent authorities, procedures for amendments,
requirements for sponsor and insurance, and adverse
event reporting applied to each clinical research catego-
ries. The main topics are summarised in the Appendix.
In addition a number of more specific questions were
raised as well as suggestions for amendments to EU clini-
cal research and its regulatory process.
The resulting survey served well its purpose, which will be
described in future publications.
Conclusion
Further work on the classification of clinical categories
proposed here is necessary both to avoid unjustified over-
lapping of categories and to ensure that the definitions are
as consistent as possible and correspond to existing scien-
tific and legal thinking. We could also consider other
existing proposals for classification. The UK Clinical
Research Collaboration has developed the Health
Research Classification System for the classification and
analysis of all types of health research [8]. The system is
two dimensional, classifying research according to the
type of research taking place (research activity codes) and
by area of health and disease (health categories). The eight
main research activity codes are underpinning research,
aetiology, prevention of disease and conditions, and pro-
motion of well-being, detection screening and diagnosis,
development of treatments and therapeutic interventions,
evaluation of treatments and therapeutic interventions,
management of diseases and conditions and health and
social care services research. This listing shows that the
research activity codes are less oriented to clinical trial
structure but covers health care research as a whole.
ECRIN is currently cooperating with the European Medi-
cal Research Council (EMRC) on its forward looks on
investigator-driven clinical trials. This document identi-
fied the adoption of common categories of clinical
research as a high priority need, and has proposed to
adopt the ECRIN categories [9,10].
In conclusion, the generation of an international survey
pointed us to the important necessity to harmonise defi-
nitions and clinical trials categories in Europe to create the
basis of a common understanding between international
investigators and to simplify the preparation of interna-
tional study protocols. We believe that the list of clinical
research categories we have used for the ECRIN survey
could serve as a contribution to the, much needed, task of
harmonisation and simplification of the regulatory
requirements for clinical research within the EU even if
further efforts are necessary as discussed. It can initiate dis-
cussion and help reach agreement on common defini-
tions of clinical trials terms and clinical research
categories, both being prerequisite to conduct efficiently
international clinical trials.
The ECRIN group will remain actively involved in the
field in order to increase its scope and specifically address
also the needs of countries currently outside its network.
Therefore, all documents developed by ECRIN will be
available at the ECRIN website http://www.ecrin.org to
stimulate discussion and exchange of ideas.
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Appendix
ECRIN survey
QUESTIONS ASKED TO EACH CATEGORY AND SUBCATEGORY 
OF CLINICAL RESEARCH AS DEFINED IN TABLE 1
Is a submission to an ethics committee required? (specify
the name of the committee and who is responsible for the
submission)Trials 2009, 10:95 http://www.trialsjournal.com/content/10/1/95
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Is a submission to competent authority required? (specify
the name of the competent authority and who is respon-
sible for the submission)
Is there a specific procedure for substantial amendments?
Is there a requirement for a sponsor in this type of trial?
Is co-sponsorship allowed?
Is insurance required? (specify who is covered: sponsor,
investigator, patients)
Adverse event (AE) reporting (Serious adverse events/Non
serious adverse events)
Specify which adverse events have to be reported by the
sponsor (or, if no sponsor, by the investigator) when and
to whom? Is a safety report requested
ADDITIONAL QUESTIONS
➢ Is there a definition for interventional vs. non-interven-
tional (or observational) clinical research?
➢ Are studies on usual care/quality studies/clinical audits
considered as a specific category?
➢ Is there a definition for non-commercial trials?
➢ Is there a definition for a non-commercial sponsor?
➢ What is the definition of investigational medicinal
products (IMP) in your country?
➢ Are there specific requirements for IMP labelling in tri-
als on medicinal products?
➢ Are there specific requirements for IMP labelling in
non-commercial trials?
➢ In non-commercial trials, is there a waiver for the spon-
sor to purchase the IMP?
➢ Are there specific requirements regarding compassion-
ate studies/use?
➢ Are there any additional requirements for studies on
biopharmaceuticals (proteins, monoclonals, DNA.)?
➢ Are there any additional requirements for studies on
biotherapy (gene-cell-tissue)?
➢ Are there specific requirements for studies using adult
stem cells?
➢ Are there specific requirements for studies using embry-
onic stem cells?
➢ Are there specific requirements for the in vivo use of
nanoparticles (for diagnostic or treatment)?
➢ Are there specific requirements for studies using animal
derived products?
➢ Are there requirements for specific populations?
(healthy volunteers/Vulnerable populations)
➢ Are there specific requirements for emergency condi-
tion or critically ill patients?
➢ Is there a waiver of informed consent under emergency
condition or critically ill patients?
➢ Are minority/ethnicity/gender taken into account in
the national legislation?
➢ Is there a national volunteer's file for participants in
clinical research?
➢ Are there compensation fees for volunteers/patients
participating in clinical research?
➢ Are there specific strategies for monitoring clinical tri-
als?
➢ Are there regulatory requirements regarding data man-
agement in clinical trials?
➢ Are there specific requirements regarding personal data
protection in clinical research?
➢ Are there specific requirements regarding blood/tissue
samples (circulation and storage)?
➢ Are there specific requirements regarding studies on
biomarkers/surrogate markers (definition or validation of
biomarkers)?
➢ Are there specific requirements regarding genetic or
genotype/phenotype studies?
➢ Is there a national plan in your country on where to reg-
ister clinical trials (a register where trial information can
be made publicly available before inclusion of the first
participant)?
➢ Is there a national plan on where to register ano-
nymised data from the trial once it has been conducted
and analysed?Publish with BioMed Central    and   every 
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➢ Is there a national plan on where to register publica-
tions deriving from the clinical trial?
➢ Is there an obligation to inform the patients on the out-
come of the clinical trial?
➢ Does the legislative system in your country cover any
biomedical research? or is it focusing on clinical research
on health products?
COMMENTS
➢ Specify the five top priority topics to improve clinical
research and provide suggestions for improvement
➢ Specify the five top priority topics to improve European
competent authority working practice and provide sugges-
tions for improvement
➢ What would be your expectations regarding future EU
regulation on clinical research?
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